Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing

Int J Lab Hematol. 2023 Feb;45(1):126-136. doi: 10.1111/ijlh.13977. Epub 2022 Oct 12.

Abstract

Introduction: Lupus anticoagulant (LA) testing requires normal pooled plasma (NPP) in performing mixing studies and can be used for normalized ratios of clotting times (CTs). The aims were to demonstrate whether significant differences in clotting times between two batches of a same commercial NPP (CRYOcheck™) directly affect NPP-based cut-off values.

Methods: Diluted Russell Viper venom time (DRVVT) and activated partial thromboplastin time (aPTT) were used for LA testing. Screening, mixing and confirm tests were performed with Stago® instruments and reagents. Two batches of commercial NPP (A1291 and A1301 from CRYOcheck™; frozen) were compared in the determination of cut-off values. Cut-off values were defined as 99th percentile values of 60 healthy donors and compared with Mann-Whitney U test.

Results: Cut-off values obtained with the two NPP batches were significantly different for DRVVT (screen normalized ratio: 1.09 vs. 1.24, screen mix: 41.9 s vs. 38.9 s; index of circulating anticoagulant: 5.0 vs. 8.4; all had p-value <.001). On the contrary, no significant differences were observed for aPTT (screen normalized ratio: 1.32 vs. 1.34; p-value = .4068, screen mix: 37.8 s vs. 38.1 s; p-value = .1153) except for index of circulating anticoagulant: 9.6 versus 10.4 (p-value <.05).

Conclusion: This study demonstrates that differences between two commercial NPP batches produced by a same manufacturer influenced LA cut-off values used for mixing studies and normalized ratios. Adequate cut-off setting, taking into account NPP CTs, is important to provide accurate conclusion about the presence or absence of a LA and avoid potential clinical impact.

Keywords: cut-off values; laboratory diagnosis; lupus anticoagulant; mixing study; normal pooled plasma.

MeSH terms

  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome*
  • Blood Coagulation Tests
  • Humans
  • Lupus Coagulation Inhibitor*
  • Partial Thromboplastin Time
  • Prothrombin Time

Substances

  • Lupus Coagulation Inhibitor
  • Anticoagulants